ArticleCancer cell2011
Resistance to EGFR-targeted therapy: a family affair.
Article in Cancer cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.Investigational new drugs · 2022Trial
- ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer.BMC genomic data · 2025Article
- Review
- Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Journal of experimental & clinical cancer research : CR · 2021Review
- NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck.Oncogenesis · 2021Article
- [Bacterial expression of 183-227aa region of HER3 extracellular domain I and preparation and identification of its polyclonal antibodies].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.Breast cancer research : BCR · 2020Article
- Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy.Advanced drug delivery reviews · 2019Review
- Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.International journal of molecular sciences · 2018Article
- HER3 signaling and targeted therapy in cancer.Oncology reviews · 2018Article
- Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma.Frontiers in oncology · 2018Article
- HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2017Article
- Review
- γ-Tocotrienol suppresses growth and sensitises human colorectal tumours to capecitabine in a nude mouse xenograft model by down-regulating multiple molecules.British journal of cancer · 2016Article
- Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.Molecular cancer therapeutics · 2016Article
- Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.Oncotarget · 2016Article
- An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis.Oncogene · 2015Article
- Generation and Characterization of Rat Monoclonal Antibodies Against Epidermal Growth Factor Receptor.Monoclonal antibodies in immunodiagnosis and immunotherapy · 2015Article
- Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.